We are contrasting Surface Oncology Inc. (NASDAQ:SURF) and Compugen Ltd. (NASDAQ:CGEN) on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surface Oncology Inc.	52.13M	3.04	17.66M	-0.54	0.00
Compugen Ltd.	17.80M	11.21	22.51M	-0.43	0.00

Table 1 demonstrates Surface Oncology Inc. and Compugen Ltd.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides us Surface Oncology Inc. and Compugen Ltd.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Surface Oncology Inc.	-33.88%	63.7%	15.3%
Compugen Ltd.	-126.46%	-65.1%	-50.1%

Liquidity

The current Quick Ratio of Surface Oncology Inc. is 6.4 while its Current Ratio is 6.4. Meanwhile, Compugen Ltd. has a Current Ratio of 4.6 while its Quick Ratio is 4.6. Surface Oncology Inc. is better positioned to pay off its short-term and long-term debts than Compugen Ltd.

Institutional & Insider Ownership

The shares of both Surface Oncology Inc. and Compugen Ltd. are owned by institutional investors at 63.4% and 18.2% respectively. About 14.85% of Surface Oncology Inc.’s share are held by insiders. Insiders Competitively, held 12% of Compugen Ltd. shares.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Surface Oncology Inc.	3.47%	-3.46%	-14.61%	-41.42%	0%	-37.28%
Compugen Ltd.	-7.23%	-8.81%	-19.75%	-12.65%	28.4%	28.4%

For the past year Surface Oncology Inc. had bearish trend while Compugen Ltd. had bullish trend.

Summary

Surface Oncology Inc. beats on 7 of the 10 factors Compugen Ltd.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.